Lyle Arnold, Ph.D.
Senior Vice President of Research & Development and Chief Scientific Officer
Dr. Arnold is a biotechnology executive, entrepreneur and developer of innovative technologies covering therapeutics, molecular diagnostics, and genomics. The author of more than 50 scientific publications, he is the principal inventor of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies. Dr. Arnold holds 36 issued U.S. patents and more than 140 issued and pending patents worldwide. Prior to joining Biocept, Dr. Arnold has worked for various companies in the clinical and diagnostics space, including Aegea Biotechnologies, Gen-Probe, Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, Oasis Biosciences and UCSD Cancer Center.
He received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.
Veena Singh, MD
Senior Medical Director
Dr. Singh brings years of laboratory diagnostics experience and a deep personal interest in blood-based biomarker testing. Prior to joining Biocept, she led the clinical laboratory team as the Medical Director at the molecular oncology diagnostics company bioTheranostics Inc. Her expertise in validating and launching assays in a CLIA lab setting, along with extensive knowledge of developmental stage biomarkers, serve as a major catalyst for Biocept’s continuing expansion of its offerings.
Dr. Singh completed a Molecular Genetic Pathology fellowship at Cedars-Sinai Medical Center in Los Angeles and an Anatomic and Clinical pathology residency at the University of California, San Diego. Dr. Singh is board certified in Anatomic and Clinical Pathology and Molecular Genetic Pathology. She received her medical degree from the University of Transkei in South Africa and is a Fellow of the College of American Pathologists and the American College of Medical Genetics.
Jason C. Poole, Ph.D.
Vice President of Operations in Research and Development
Dr. Poole specializes in the development of complex molecular diagnostic tests for use in human health and disease using non-invasive methods. He has spent the past 20-years leading research and development efforts in the fields of oncology, reproductive biology and infectious disease. His expertise lies in product development using advanced techniques in Next Generation Sequencing, qPCR, and nucleic acid sample preparation. Prior to joining Biocept, he served as the Director of R&D at Trovagene, Inc. As a Postdoctoral Fellow at UC, Irvine’s Center for Molecular Medicine he received a National Research Service Award from the NIH’s National Institute on Aging.
A graduate of the University of Colorado, Dr. Poole received his M.S. in Molecular Endocrinology from Northwestern University and his Ph.D. in Molecular Genetics from the University of Illinois School of Medicine in Chicago, IL.
Cecile Rose Vibat, Ph.D.
Senior Director, Clinical and Translational Affairs
Dr. Vibat has more than 15 years of biotechnology industry experience with roles in both scientific laboratory research and clinical affairs. Prior to joining Biocept, she held scientific positions in various molecular diagnostics companies, including Trovagene, Digital Gene Technologies, Neurome, and Sequenom, leading laboratory teams and managing operations of contract genetic analysis services.
Dr. Vibat received her Bachelor’s degree in Biochemistry from the University of California, Berkeley and her Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign. She is a certified Project Management Professional (PMP).
Julie Mayer, Ph.D.
Senior Director, Laboratory Operations
Dr. Mayer adds a wealth of relevant oncology product development and validation experience to the leadership team at Biocept. She has held scientific and management positions at several molecular diagnostics companies, including Navigate BioPharma Services (A Novartis Subsidiary), Genoptix, and Biocept. As a leader in biomarker discovery and the integration of technology, she has developed, validated, and transferred >20 Molecular Diagnostic Assays for production and clinical trial testing in multiple CLIA/CAP accredited laboratories.
She holds a M.S. in Experimental and Molecular Pathology and Ph.D in Pathology both from the University of Southern California. Dr. Mayer received her post-doctoral training in Translational Breast Cancer Research at Baylor College of Medicine and in Clinical Cancer Prevention at MD Anderson Cancer Center.
Tony J. Pircher, Ph.D.
Director of Immunochemistry
Dr. Pircher leads the identification and validation of tumor specific markers for the enrichment and detection of rare circulating tumor cells (CTC) and development of predictive and/or prognostic CTC assays. He has extensive experience in developing proteomic and genomic diagnostic assays and is the inventor on several Biocept patents.
He received his Ph.D. in molecular endocrinology from the Karolinska Institute, Stockholm, mentored by Dr. Lars-Arne Haldosen and the world renowned steroid receptor scientist Dr. Jan-Ake Gustafsson. During his postdoctoral training, he worked in the field of molecular hematology at the Pennsylvania State University in the highly prolific research lab of Dr. Don M Wojchowski, where he gained extensive experience in the enrichment of erythroid progenitor cells from blood, bone marrow and spleen.
Director of Technology Development
Pavel Tsinberg is one of the original developers of the cell separation device. His multidisciplinary background is useful for integrating engineering, biology, and surface chemistry with clinical assays. Pavel has worked in biotechnology since 1999, focusing on microarrays, prenatal diagnostics, and, finally, CTC detection. He is an inventor or co-inventor on the majority of Biocept’s patents, and is currently involved in developing the next generation of Biocept’s technology platform.
Pavel received a B.S.E in Bioengineering from Columbia University SEAS, and a M.S.E in Biomedical engineering from University of Pennsylvania.